Emerging treatments
Coagulation factor VIIa (recombinant)
Recombinant coagulation factor VIIa (known as eptacog alfa in some countries) is approved in Europe for the treatment of severe postpartum haemorrhage if uterotonic agents are insufficient to achieve haemostasis. However, it is not approved in the US for this indication. Results from clinical trials evaluating coagulation factor VIIa in this indication are yet to be published, and further data are required to clearly indicate safety in all cases of postpartum haemorrhage.
Use of this content is subject to our disclaimer